Neurology

First patient dosed in Phase 1 clinical trial for preventive migraine treatment

The first individuals have been dosed in a Phase 1 clinical trial of UB-313, a vaccine targeting calcitonin gene-related peptide (CGRP), for the preventive treatment of migraine, according to a press release by Vaxxinity, Inc. The trial will enroll 40 healthy volunteers and will evaluate safety, tolerability, and immunogenicity, measured...